The ACCESS-SMC project* has proven the feasibility, safety and effectiveness of seasonal malaria chemoprevention at scale. With areas in the Sahel having the highest incidence of malaria in the world, it is now time to look towards reaching all 25 million eligible children.

**SMC is safe**

Over 50 million treatments were administered by ACCESS-SMC in the last three years. Severe adverse reactions were very uncommon, and a safety review found no safety concerns.

**Invest in SMC**

With more funding, it is possible to reach all eligible children in the Sahel. The time to invest is now. Drugs are available and effective, and the scale-up has proven successful.

*ACCESS-SMC is a UNITAID funded project, led by Malaria Consortium in partnership with Catholic Relief Services, which is supporting National Malaria Control Programs to scale up access to seasonal malaria chemoprevention to save children’s lives across seven countries in the Sahel. By demonstrating the feasibility and impact of SMC at scale, ACCESS-SMC will promote the intervention’s wider adoption.

**SP+AQ is a combination of sulfadoxine pyrimethamine plus amodiaquine drugs used in SMC as an antimalarial preventive treatment course."